Sökning: onr:"swepub:oai:DiVA.org:uu-102695" > Utilization of a ri...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03060naa a2200481 4500 | |
001 | oai:DiVA.org:uu-102695 | |
003 | SwePub | |
008 | 090511s2009 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:118353336 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1026952 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1183533362 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Eriksson, Mathildau Karolinska Institutet4 aut |
245 | 1 0 | a Utilization of a right-handed coiled-coil protein from archaebacterium Staphylothermus marinus as a carrier for cisplatin |
264 | 1 | c 2009 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: The nano-sized right-handed coiled-coil (RHCC) protein, originating from the archaebacterium Staphylothermus marinus, is stable at high salt concentrations, high temperatures, high pressures and extremes of pH. Its crystal structure reveals four hydrophobic cavities which can incorporate heavy metals. Nano-sized compounds have been used to carry cytotoxic drugs to tumours, avoiding delivery to healthy tissue, in part due to enhanced permeability in tumour blood vessels (enhanced permeability and retention effect). MATERIALS AND METHODS: The ability of RHCC to carry the platinum-containing chemotherapeutic drug cisplatin to cells, while retaining the cytotoxic potential was tested both in vitro and in vivo. RESULTS: RHCC was able to bind and enter cells in vitro and was not severely toxic or immunogenic in mice. Moreover, RHCC incorporated cisplatin, without inhibiting the cytotoxic potential of the drug against tumour cell lines in vitro or in vivo. CONCLUSION: RHCC can be used as a carrier of cisplatin without abrogating the effect of the drug. | |
653 | a RHCC | |
653 | a cisplatin | |
653 | a nano | |
653 | a carrier | |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Hassan, Saadiau Uppsala universitet,Klinisk farmakologi,Cancer Pharmacology and Informatics4 aut0 (Swepub:uu)sadihass |
700 | 1 | a Larsson, Rolfu Uppsala universitet,Klinisk farmakologi,Cancer Pharmacology and Informatics4 aut0 (Swepub:uu)rolflars |
700 | 1 | a Linder, Stigu Karolinska Institutet4 aut |
700 | 1 | a Ramqvist, Torbjörnu Karolinska Institutet4 aut |
700 | 1 | a Lövborg, Henrik4 aut |
700 | 1 | a Vikinge, Trine4 aut |
700 | 1 | a Figgemeier, Egbert4 aut |
700 | 1 | a Müller, Jürgen4 aut |
700 | 1 | a Stetefeld, Jörg4 aut |
700 | 1 | a Dalianis, Tinau Karolinska Institutet4 aut |
700 | 1 | a Ozbek, Suat4 aut |
710 | 2 | a Karolinska Institutetb Klinisk farmakologi4 org |
773 | 0 | t Anticancer Researchg 29:1, s. 11-18q 29:1<11-18x 0250-7005x 1791-7530 |
856 | 4 | u http://ar.iiarjournals.org/content/29/1/11.full.pdf+htmly Fulltext |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-102695 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:118353336 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy